Asia Pacific active pharmaceutical ingredients market will grow by 8.8% annually with a total addressable market cap of $691.3 billion over 2021-2028, driven by rising adoption of biologics in disease management, increasing regulatory approvals, patent expiration of major drugs, growing trend of outsourcing and increase in geriatric population.
Highlighted with 92 tables and 68 figures, this 192-page report Asia Pacific Active Pharmaceutical Ingredients (API) Market 2021-2028 by Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Country: Trend Forecast and Growth Opportunity is based on comprehensive research of the entire Asia Pacific active pharmaceutical ingredients market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2028 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
Market Structure
Growth Drivers
Restraints and Challenges
Emerging Product Trends & Market Opportunities
Porters Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific active pharmaceutical ingredients market in every aspect of the classification from perspectives of Synthesis, Manufacturing Process, Therapeutic Application, Drug Type, and Country.
Based on Synthesis, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2018-2028 included in each section.
Synthetic API
Branded Synthetic API
Generic Synthetic API
Biotech API by Drug Type:
Monoclonal Antibodies
Recombinant Proteins
Vaccines
Other Biotech APIs
Biotech API by Customer Base:
Innovative Biologic API
Generic Biosimilar API
Biotech API by Expression Technology:
Mammalian Expression
Microbial Expression
Yeast Expression
Insect Expression
Other Expression Technologies
HPAPI
Branded HPAPI
Generic HPAPI
Based on Manufacturing Process, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2018-2028 included in each section.
Captive Manufacturing
Branded Captive API
Generic Captive API
Merchant Manufacturing by Drug Type:
Branded Merchant API
Generic Merchant API
Merchant Manufacturing by Drug Synthesis:
Merchant Synthetic API
Merchant Biotech API
By Therapeutic Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2018-2028 included in each section.
Infectious Diseases
Oncology
Ophthalmology
Cardiovascular Disorders
Central Nervous System
Pulmonary Disorders
Orthopedics
Other Applications
By Drug Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2018-2028 included in each section.
Branded Prescription Drugs
Generic Prescription Drugs
OTC Drugs
Geographically, the following national/local markets are fully investigated:UK
Japan
China
South Korea
Australia
India
Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual revenue ($ bn) are available for 2018-2028. The breakdown of key national markets by Synthesis, Manufacturing Process, and Therapeutic Application, over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
AbbVie Inc.
Astrazeneca
Aurobindo Pharma Ltd.
BASF
Bayer AG
Boehringer Ingelheim
Catalent Inc.
Dr. Reddy's Laboratories
F. Hoffmann-La Roche
GlaxoSmithKline plc
Lonza Group
Lupin Limited
Merck & Co., Inc.
Mylan NV
Novartis International AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Thermo Fisher Scientific
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
